VanEck Advisor: The long-term impact of Bitcoin ETF has been greatly underestimated
Gabor Gurbacs, an advisor at VanEck, has stated on social media that the long-term impact of Bitcoin ETFs is greatly underestimated. Institutions are serious about Bitcoin. The stigma has been removed and channels have opened up. On November 18, 2004, SPDR (State Street) Gold ETF (GLD) was launched. In the subsequent eight years, the price of gold doubled from $400 to $1800 and its market value increased from $2 trillion to $10 trillion, adding approximately $8 trillion. Today, the market value of Bitcoin is around $800 billion which is a quarter of gold's market value in 2004. In my view, Bitcoin's price trajectory may follow the blueprint of gold in 2004 and subsequent years. It's worth noting that enthusiasm for some institutional bitcoin products and inflows of between $20 billion to $30 billion could significantly boost bitcoin prices due to: 1) relatively low circulation volume (strong hands/long-term holders); 2) systematic scarcity through halving plans.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
